Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENG PHARMACEUTICAL CO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022035
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Suggestive announcement on the disclosure of the plan for non-public offering of shares
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”) convened the fourth extraordinary meeting of the Fifth Board of directors in 2022 and the fourth extraordinary meeting of the Fifth Board of supervisors in 2022 on March 4, 2022, and deliberated and approved the relevant proposals of the company’s non-public offering of shares in 2022. For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on March 7, 2022 Public announcements such as Hunan Fangsheng Pharmaceutical Co.Ltd(603998) 2022 stock plan of non-public development banks disclosed. Please pay attention to the majority of investors.
The disclosure of the non-public offering plan does not represent the substantive judgment, confirmation or approval of the examination and approval authority on the matters related to the non-public offering. The effectiveness and completion of the matters related to the non-public offering described in the plan are subject to the deliberation and approval of the company’s general meeting of shareholders and the approval of the relevant examination and approval authority. Please pay attention to the investment risks.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
March 6, 2022
